CERO Therapeutics Holdings, Inc. announced on April 24, 2025, that the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado, will serve as a key clinical trial site for its Phase 1 clinical trial of CER-1236. This trial focuses on patients with acute myeloid leukemia (AML).
Patient enrollment for the trial is currently underway, with the first dosing of the initial cohort of patients expected by June. CBCI is recognized as a leader in blood cancer care, serving a seven-state region, and its participation is expected to enhance the trial's reach and credibility.
Dr. Yazan Migdady, an investigator in the trial, commented that the use of chimeric engulfment receptor technology in cellular therapy for AML offers new hope for patients. CEO Chris Ehrlich stated that CBCI's involvement further validates the scientific work performed to date with CER-1236.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.